Literature DB >> 10529775

What is the real role of CD40 in cancer immunotherapy?

R T Costello1, J A Gastaut, D Olive.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10529775     DOI： 10.1016/s0167-5699(99)01507-8

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  6 in total

1.  Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.

Authors:  Peter Ellmark; Camilla Ottosson; Carl A K Borrebaeck; Ann-Christin Malmborg Hager; Christina Furebring
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

2.  microRNA signature for human pancreatic cancer invasion and metastasis.

Authors:  He Cheng; Si Shi; Xiaochen Cai; Jiang Long; Jin Xu; Chen Liu; Xianjun Yu
Journal:  Exp Ther Med       Date:  2012-05-21       Impact factor: 2.447

3.  Regulation of CD40 function by its isoforms generated through alternative splicing.

Authors:  M Tone; Y Tone; P J Fairchild; M Wykes; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 4.  Immunotherapies targeting stimulatory pathways and beyond.

Authors:  Julian A Marin-Acevedo; ErinMarie O Kimbrough; Rami Manochakian; Yujie Zhao; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2021-05-12       Impact factor: 17.388

5.  Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.

Authors:  Ying Li; Jiani Yuan; Qian Yang; Wei Cao; Xuanxuan Zhou; Yanhua Xie; Honghai Tu; Ya Zhang; Siwang Wang
Journal:  Int J Nanomedicine       Date:  2014-12-04

Review 6.  Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies.

Authors:  Da-Ke Li; Wen Wang
Journal:  Oncol Lett       Date:  2020-08-31       Impact factor: 2.967
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.